Showing 13 - 19 of 19 reports matching: Tumour
Journals
Specialties
Date of Publication
to
Synopsis: 647 patients with localized Ewing sarcoma were sorted into two risk groups based on the stage and tumour volume. Patients were allocated to the standard-risk (SR) group if their localized tumours were less than 100 mL in volume. Patients with localized Read More »
Level 2 RCT
Synopsis: 246 patients with nonmetastatic osteosarcoma were randomized to evaluate the addition of ifosfamide to a primary chemotherapy regimen of methotrexate, cisplatin, and doxorubicin, with patients allocated to chemotherapy with or without ifosfamide. After a median follow-up of 76 months, there was no difference between groups in overall survival, event-free survival, and the percentage of patients with a good response to primary chemotherapy. Moreover, those treated Read More »
Author verified Level 2 RCT
Synopsis: 568 patients with localized Ewing sarcoma were randomized to receive alternating cycles of vincristine - doxorubicin - cyclophosphamide and ifosfamide-etoposide chemotherapy either every 14 or 21 days. Between cycles patients were administered filgrastim and at week 13 all patients received primary tumour treatment. The purpose of Read More »
Author verified Level 2 RCT
Synopsis: 478 patients under the age of 30, diagnosed with non-metastatic ESFT (or the Ewing sarcoma family of tumours), were randomized to either a standard or intensified dose regimen of vincristine, doxorubicin, and cyclophosphamide (VDC) along with ifosfamide and etoposide (IE) to assess the 5-year event-free and overall survival rates between groups. Results indicated that there was no significant difference between groups in the 5-year event-free and overall survival rates or the incidence of secondary leukemia. However, the frequency Read More »
Level 2 RCT
Synopsis: 91 patients with metastatic osteosarcoma were randomized to receive a 3-drug treatment of chemotherapy (cisplatin, doxorubicin, and high-dose methotrexate) with or without ifosfamide. Within each group patients were further randomized to either receive liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) or not to determine whether the addition of liposomal MTP-PE to chemotherapy was effective in improving survival. After a median Read More »
Level 2 RCT
Synopsis: Eighteen studies (6 case series, 10 retrospective reviews, and 2 prospective studies) consisting of 760 patients were evaluated to determine what the mean volume of blood loss was during spinal tumour surgery and surgery for metastatic spinal disease. Results indicated that Read More »
Author verified Meta Analysis
Synopsis: 59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for implications in prognosis. Results demonstrated a Read More »
Author verified Level 2 RCT